Adagloxad simolenin (OBI Pharma) is a carbohydrate-based vaccine comprised of Globo-H conjugated to keyhole limpet hemocyanin. Upon exposure to the synthetic Globo-H vaccine and an immunological adjuvant, the immune system mounts IgM and IgG responses against Globo-H hexasaccharide. The antibodies produced are selectively reactive against Globo-H positive cell lines and can induce lysis of Globo-H positive cells. This depletion of Globo-H positive cells inhibits immunosuppression by increasing Notch1 signaling through decreased expression of id3 and itch, which promotes T-cell activation. Globo-H-hexasaccharide, which is expressed on the cancer cell surface as a glycolipid, is not usually present in normal tissues but has been found to be highly expressed in breast, prostate, and lung cancers.
4 Drug Overview
5 Product Profiles
5 adagloxad simolenin : Breast cancer: triple-negative
LIST OF FIGURES
10 Figure 1: Datamonitor Healthcare’s drug assessment summary of adagloxad simolenin for TNBC
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of adagloxad simolenin for TNBC
LIST OF TABLES
6 Table 1: Adagloxad simolenin drug profile
8 Table 2: Late-phase trials of adagloxad simolenin for TNBC
9 Table 3: Adagloxad simolenin for TNBC – SWOT analysis
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726